摘要
目的分析瑞舒伐他汀辅治冠心病经皮冠状动脉介入治疗(PCI)后可溶性细胞间粘附因子(s ICAM-1)、红细胞分布宽度(RDW)、血管性血友病因子(vWF)水平变化与支架内再狭窄的关系。方法选取2018年7月至2020年1月于本院接受治疗的124例冠心病患者作为冠心病组,随访1年,根据随访记录中支架内再狭窄发生情况分为再狭窄组和无狭窄组。选取91例同期于本院进行全面体检且健康者作为对照组。比较2组SICAM-1、RDW及vWF水平变化,采用多元Logistic回归分析影响冠心病患者治疗后发生支架内再狭窄的独立危险因素。结果冠心病组治疗前SICAM-1、RDW及vWF水平高于对照组,差异具有统计学意义(P<0.05)。冠心病组治疗2周后SICAM-1、RDW及vWF水平较治疗前有所升高,差异具有统计学意义(P<0.05)。再狭窄组年龄、BMI、高血压病史、糖尿病病史、低密度脂蛋白胆固醇、SICAM-1、RDW及vWF水平和吸烟情况与无狭窄组比较差异有统计学意义(P<0.05)。SICAM-1、RDW及vWF水平异常升高是影响冠心病患者治疗后发生支架内再狭窄的独立危险因素(P<0.05)。结论经瑞舒伐他汀辅助PCI治疗冠心病患者SICAM-1、RDW及vWF水平变化与支架内再狭窄关系密切,临床需密切监测上述指标水平变化并及时干预,以降低支架内再狭窄发生风险。
Objective To analyze the relationship between the change in the levels of soluble intercellular adhesion molecule-1(sICAM-1),red cell volume distribution width(RDW)and von Willebrand factor(vWF)and in-stent restenosis after percutaneous coronary intervention(PCI)and adjuvant treatment with rosuvastatin in patients with coronary heart disease.Methods The 124 patients with coronary heart disease who were treated in this hospital from July 2018 to January 2020 were selected as the coronary heart disease group,the patients were followed up for 1 year.According to in-stent restenosis in the follow-up records after PCI operation,they were divided into the restenosis group and the non-stenosis group.91 healthy patients who had a comprehensive physical examination in our hospital during the same period were selected as the control group.The changes in SICAM-1,RDW and vWF levels between the two groups were compared,and the multivariate logistic regression was used to analyze the independent risk factors that affect the occurrence of in-stent restenosis in patients with coronary heart disease after treatment.Results The levels of SICAM-1,RDW and vWF in the coronary heart disease group before treatment were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of SICAM-1,RDW and vWF in the coronary heart disease group increased 2 weeks after treatment,and the difference was statistically significant(P<0.05).The differences were statistically significant in age,BMI,history of hypertension,history of diabetes,low-density lipoprotein cholesterol,SICAM-1,RDW and vWF levels,and smoking between the restenosis group and the non-stenosis group(P<0.05).The abnormal increase of SICAM-1,RDW and v WF levels are independent risk factors that affect the occurrence of in-stent restenosis after treatment in patients with coronary heart disease(P<0.05).Conclusion The changes of SICAM-1,RDW,and v WF in patients with coronary heart disease after PCI and adjuvant treatment with rosuvastatin are closely related to the occurrence of in-stent restenosis.Clinically,it is necessary to closely monitor the changes in the levels of the above indicators and intervene in time to reduce the risk of in-stent restenosis.
作者
崔耀刚
吕小宁
庞然
CUI Yaogang;LV Xiaoning;PANG Ran(Department of Cardiology,General Hospital of Yima Coal Industry Group Co.,Ltd.,Yima,Henan,China,472300;Department of Internal Medicine-Cardiovascular,General Hospital of Yima Coal Industry Group Co.,Ltd.,Yima,Henan,China,472300)
出处
《分子诊断与治疗杂志》
2022年第3期426-429,共4页
Journal of Molecular Diagnostics and Therapy
基金
河南省科技攻关计划(201802135)。
作者简介
通信作者:崔耀刚,E⁃mail:rangp17111@163.com。
